Macro Group Pharmaceutical SAE (MCRO)

Currency in EGP
1.69
+0.16(+10.46%)
Closed·

MCRO Financial Summary

Key Ratios

P/E Ratio6.05
Price/Book3.56
Debt / Equity171.94%
Return on Equity85.15%
Dividend Yield0.00%
EBITDA140.42M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
2025
31/12
* In Millions of EGP (except for per share items)

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 1.57
(-7.10% Downside)

Earnings

Latest Release
Feb 19, 2026
EPS / Forecast
0.02 / --
Revenue / Forecast
216.28M / --
EPS Revisions
Last 90 days

FAQ

What were Macro Pharmaceutical's earnings for the latest quarter?

The Macro Pharmaceutical EPS (TTM) is 0.20. Macro Pharmaceutical reported sales of 216.28, net income of 11.84, and EPS of 0.02 for the latest quarter.

What was Macro Pharmaceutical's net income for the latest quarter?

Macro Pharmaceutical's net income for the latest quarter was 11.84.

How did Macro Pharmaceutical's performance compare year-over-year in the latest quarter?

The company's revenue moved from 266.72 million EGP in the previous quarter to 216.28 million EGP in the latest quarter, and net income moved from 34.98 million EGP to 11.84 million EGP compared to the previous quarter.

What is Macro Pharmaceutical's net profit margin on a TTM basis?

Macro Pharmaceutical's trailing twelve months (TTM) net profit margin is 12.94%.

How does Macro Pharmaceutical's debt to equity ratio compare to industry standards?

Macro Pharmaceutical's total debt-to-equity ratio is 171.94%.

What is Macro Pharmaceutical's return on investment on a TTM basis?

Macro Pharmaceutical's trailing twelve months (TTM) return on investment (ROI) is 85.15%.

How has Macro Pharmaceutical's total revenue grown this year?

Macro Pharmaceutical's total revenue was 266.72 million EGP in the previous quarter and 216.28 million EGP in the latest quarter.

What is Macro Pharmaceutical's gross margin on a TTM basis?

Macro Pharmaceutical's trailing twelve months (TTM) gross margin is 68.11%%.

What was Macro Pharmaceutical's revenue per share for the latest quarter?

Macro Pharmaceutical's revenue per share for the latest quarter was 134.35.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.